Summit Therapeutics (SMMT) Reports Q1 Loss of GBP0.09/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2016 and Operational Progress
June 2, 2016 7:01 AM EDTOXFORD, United Kingdom, June 02, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM: SUMM) (NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (DMD) and C. difficile infection (CDI), today reports its financial results for the first quarter ended 30 April 2016. Â Â
Mr Glyn Edwards, Chief Executive Officer of Summit commented: Our programmes in DMD and CDI both have the potential to significantly improve the current standards of care and are making good progress towards the patients who could... More
Summit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2016 on 2 June 2016
May 31, 2016 7:00 AM EDTOXFORD, United Kingdom, May 31, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM: SUMM) (NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be reporting its first quarter financial results for the... More
